Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c

Fred Saad; Sebastien Hotte; Scott North; Bernie Eigl; Kim Chi; Piotr Czaykowski; Lori Wood; Michael Pollak; Scott Berry; Jean Baptiste Lattouf; Som D. Mukherjee; Martin Gleave; Eric Winquist

doi:10.1158/1078-0432.CCR-11-0859

Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c

Fred Saad, Sebastien Hotte, Scott North, Bernie Eigl, Kim Chi, Piotr Czaykowski, Lori Wood, Michael Pollak, Scott Berry, Jean Baptiste Lattouf, Som D. Mukherjee, Martin Gleave, Eric Winquist

科研成果: 期刊稿件 › 文章 › 同行评审

116 引用（Scopus）

源语言	英语
页（从-至）	5765-5773
页数	9
期刊	Clinical Cancer Research
卷	17
期	17
DOI	https://doi.org/10.1158/1078-0432.CCR-11-0859
出版状态	已出版 - 9月 1 2011
已对外发布	是

!!!ASJC Scopus Subject Areas

肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1158/1078-0432.CCR-11-0859

其它文件与链接

指纹

探究 'Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c' 的科研主题。它们共同构成独一无二的指纹。

引用此

Saad, F., Hotte, S., North, S., Eigl, B., Chi, K., Czaykowski, P., Wood, L., Pollak, M., Berry, S., Lattouf, J. B., Mukherjee, S. D., Gleave, M., & Winquist, E. (2011). Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clinical Cancer Research, 17(17), 5765-5773. https://doi.org/10.1158/1078-0432.CCR-11-0859

Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. / Saad, Fred; Hotte, Sebastien; North, Scott 等.
在: Clinical Cancer Research, 卷 17, 号码 17, 01.09.2011, 页码 5765-5773.

科研成果: 期刊稿件 › 文章 › 同行评审

Saad, F, Hotte, S, North, S, Eigl, B, Chi, K, Czaykowski, P, Wood, L, Pollak, M, Berry, S, Lattouf, JB, Mukherjee, SD, Gleave, M & Winquist, E 2011, 'Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c', Clinical Cancer Research, 卷 17, 号码 17, 页码 5765-5773. https://doi.org/10.1158/1078-0432.CCR-11-0859

Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P 等. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clinical Cancer Research. 2011 9月 1;17(17):5765-5773. doi: 10.1158/1078-0432.CCR-11-0859

@article{d29f8f9be18f4a2ba480df9bdf284961,

title = "Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c",

author = "Fred Saad and Sebastien Hotte and Scott North and Bernie Eigl and Kim Chi and Piotr Czaykowski and Lori Wood and Michael Pollak and Scott Berry and Lattouf, {Jean Baptiste} and Mukherjee, {Som D.} and Martin Gleave and Eric Winquist",

year = "2011",

month = sep,

day = "1",

doi = "10.1158/1078-0432.CCR-11-0859",

language = "English",

volume = "17",

pages = "5765--5773",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "17",

}

TY - JOUR

T1 - Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel

T2 - CUOG trial P-06c

AU - Saad, Fred

AU - Hotte, Sebastien

AU - North, Scott

AU - Eigl, Bernie

AU - Chi, Kim

AU - Czaykowski, Piotr

AU - Wood, Lori

AU - Pollak, Michael

AU - Berry, Scott

AU - Lattouf, Jean Baptiste

AU - Mukherjee, Som D.

AU - Gleave, Martin

AU - Winquist, Eric

PY - 2011/9/1

Y1 - 2011/9/1

UR - http://www.scopus.com/inward/record.url?scp=80052468423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052468423&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-0859

DO - 10.1158/1078-0432.CCR-11-0859

M3 - Article

C2 - 21788353

AN - SCOPUS:80052468423

SN - 1078-0432

VL - 17

SP - 5765

EP - 5773

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 17

ER -